PT2976074T - Antagonistas do receptor canabinóide cb1 para utilização no tratamento de doenças associadas a anomalias dendríticas neuronais - Google Patents
Antagonistas do receptor canabinóide cb1 para utilização no tratamento de doenças associadas a anomalias dendríticas neuronaisInfo
- Publication number
- PT2976074T PT2976074T PT137108502T PT13710850T PT2976074T PT 2976074 T PT2976074 T PT 2976074T PT 137108502 T PT137108502 T PT 137108502T PT 13710850 T PT13710850 T PT 13710850T PT 2976074 T PT2976074 T PT 2976074T
- Authority
- PT
- Portugal
- Prior art keywords
- cannabionoid
- antagonists
- receptor
- treatment
- diseases associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/055728 WO2014146699A1 (en) | 2013-03-19 | 2013-03-19 | Antagonists of the cannabionoid receptor cb1 for use in the treatment of diseases associated with neuronal dendritic abnormalities |
| EP13710850.2A EP2976074B1 (en) | 2013-03-19 | 2013-03-19 | Antagonists of the cannabionoid receptor cb1 for use in the treatment of diseases associated with neuronal dendritic abnormalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT2976074T true PT2976074T (pt) | 2020-03-11 |
Family
ID=47901995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT137108502T PT2976074T (pt) | 2013-03-19 | 2013-03-19 | Antagonistas do receptor canabinóide cb1 para utilização no tratamento de doenças associadas a anomalias dendríticas neuronais |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9662320B2 (pt) |
| EP (1) | EP2976074B1 (pt) |
| CY (1) | CY1122879T1 (pt) |
| DK (1) | DK2976074T3 (pt) |
| ES (1) | ES2781756T3 (pt) |
| HR (1) | HRP20200324T1 (pt) |
| HU (1) | HUE048755T2 (pt) |
| LT (1) | LT2976074T (pt) |
| PL (1) | PL2976074T3 (pt) |
| PT (1) | PT2976074T (pt) |
| RS (1) | RS60295B1 (pt) |
| SI (1) | SI2976074T1 (pt) |
| SM (1) | SMT202000164T1 (pt) |
| WO (1) | WO2014146699A1 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2514054A (en) | 2011-09-29 | 2014-11-12 | Gw Pharma Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2549277B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
| GB2549278B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| KR20250069704A (ko) * | 2017-06-30 | 2025-05-19 | 체이스 테라퓨틱스 코포레이션 | 우울증을 치료하기 위한 nk-1 길항제 조성물 및 우울증 치료에 사용하는 방법 |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| EP3669876A1 (en) * | 2018-12-18 | 2020-06-24 | Aelis Farma | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
| US20060172019A1 (en) | 2003-03-07 | 2006-08-03 | Ralston Stuart H | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
| WO2005091987A2 (en) * | 2004-03-19 | 2005-10-06 | Axonyx, Inc. | Method of treating down syndrome |
| WO2005120496A2 (en) * | 2004-05-24 | 2005-12-22 | Regents Of The University Of California | TREATING LEARNING DEFICITS WITH INHIBITORS OF HMG CoA REDUCTASE |
| WO2006012403A1 (en) * | 2004-07-20 | 2006-02-02 | Massachusetts Institute Of Technology | Methods of treatment: cell signaling and glutamate release |
| WO2006124506A2 (en) * | 2005-05-13 | 2006-11-23 | Abbott Laboratories | Combination and use of drugs |
| AU2007211613C1 (en) | 2006-02-02 | 2018-01-04 | Novartis Ag | Tuberous Sclerosis treatment |
| US20080004313A1 (en) * | 2006-06-28 | 2008-01-03 | Mai De Ltd. | Preparation of crystalline polymorphs of rimonabant hydrochloride |
| US8003672B2 (en) * | 2008-04-21 | 2011-08-23 | Merck Sharp & Dohme Corp. | CB-1 receptor modulator formulations |
| WO2010020585A1 (en) * | 2008-08-18 | 2010-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Serotonin reuptake inhibitors for the treatment of rett syndrome |
| WO2011109398A2 (en) * | 2010-03-02 | 2011-09-09 | President And Fellows Of Harvard College | Methods and compositions for treatment of angelman syndrome and autism spectrum disorders |
-
2013
- 2013-03-19 RS RS20200303A patent/RS60295B1/sr unknown
- 2013-03-19 WO PCT/EP2013/055728 patent/WO2014146699A1/en not_active Ceased
- 2013-03-19 HR HRP20200324TT patent/HRP20200324T1/hr unknown
- 2013-03-19 US US14/778,266 patent/US9662320B2/en active Active
- 2013-03-19 DK DK13710850.2T patent/DK2976074T3/da active
- 2013-03-19 LT LTEP13710850.2T patent/LT2976074T/lt unknown
- 2013-03-19 PT PT137108502T patent/PT2976074T/pt unknown
- 2013-03-19 EP EP13710850.2A patent/EP2976074B1/en active Active
- 2013-03-19 ES ES13710850T patent/ES2781756T3/es active Active
- 2013-03-19 SI SI201331699T patent/SI2976074T1/sl unknown
- 2013-03-19 HU HUE13710850A patent/HUE048755T2/hu unknown
- 2013-03-19 PL PL13710850T patent/PL2976074T3/pl unknown
- 2013-03-19 SM SM20200164T patent/SMT202000164T1/it unknown
-
2020
- 2020-03-19 CY CY20201100258T patent/CY1122879T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2976074T3 (da) | 2020-03-30 |
| EP2976074A1 (en) | 2016-01-27 |
| US20160067235A1 (en) | 2016-03-10 |
| CY1122879T1 (el) | 2021-05-05 |
| LT2976074T (lt) | 2020-03-25 |
| US9662320B2 (en) | 2017-05-30 |
| SI2976074T1 (sl) | 2020-07-31 |
| SMT202000164T1 (it) | 2020-05-08 |
| WO2014146699A1 (en) | 2014-09-25 |
| EP2976074B1 (en) | 2020-01-01 |
| RS60295B1 (sr) | 2020-07-31 |
| HRP20200324T1 (hr) | 2020-06-12 |
| ES2781756T3 (es) | 2020-09-07 |
| PL2976074T3 (pl) | 2020-07-27 |
| HUE048755T2 (hu) | 2020-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2976074T (pt) | Antagonistas do receptor canabinóide cb1 para utilização no tratamento de doenças associadas a anomalias dendríticas neuronais | |
| SG10201709090UA (en) | Sobetirome in the treatment of myelination diseases | |
| PL2968218T3 (pl) | Skojarzenie do leczenia choroby parkinsona | |
| PT3811943T (pt) | Composto para uso no tratamento de distúrbios oculares | |
| HRP20190356T1 (hr) | Mimetici kalcitonina za liječenje bolesti i poremećaja | |
| SI2945642T1 (sl) | Protein faktorja 1 za uporabo pri zdravljenju ali preprečevanju bolezni | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| EP2900266A4 (en) | TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASES | |
| HUS2000020I1 (hu) | Ciklezonid a légúti betegségek kezelésére lovaknál | |
| EP2983648A4 (en) | COMBINATION THERAPEUTIC NANOPARTICLES | |
| HUE051527T2 (hu) | Muszkarin-antagonisták és kombinációik légúti betegség lovakban történõ kezelésére | |
| EP3177304A4 (en) | Therapeutic nanoparticles for accumulation in the brain | |
| PL2774991T3 (pl) | System dostarczania leków do stosowania w leczeniu lub diagnostyce zaburzeń neurologicznych | |
| SG10201801200PA (en) | An h3 receptor antagonist for use in the treatment of alzheimer's disease | |
| LT2956136T (lt) | D-fagominas, skirtas autoimuninių ligų pradžios prevencijai | |
| EP2958570A4 (en) | THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PERIANAL DISORDERS | |
| GB201320112D0 (en) | Calcitonin Mimetics for treating diseases and disorders | |
| GB201306413D0 (en) | The local treatment of ophthalmic diseases |